Eribulin in mTNBC Patients

Completed

• Conditions: Breast Cancer

• Registration Number: NCT04541420
• Lead Sponsor: Fudan University

Brief Summary

To evaluate the efficacy and safety of Eribulin in patients with advanced breast cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-12-15
• Study First Submitted: 2020-09-02
• Study First Submitted QC: 2020-09-02
• Study First Posted: 2020-09-09
• Primary Completion: 2020-12-15
• Study Completion: 2020-12-20
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-02
• Last Update Posted: 2021-02-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 208

Inclusion Criteria

1. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
2. Eribulin treatment of advanced breast cancer for at least one cycle, between Dec 2019 and Aug 2020.
3. Available medical history.

Read More

Exclusion Criteria

1. Incomplete medical history.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PFS	6 weeks	Progression free survival
Adverse events	6 weeks	Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)

Trial Locations

Locations (1)

Fudan University Shanghai Cancer Center; 🇨🇳 Shanghai, Shanghai, China